

27 March 2018 EMA/HMPC/432278/2015 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on *Fragaria vesca* L., *Fragaria moschata* Weston, *Fragaria viridis* Weston and *Fragaria x ananassa* (Weston) Duchesne ex Rozier, folium Draft

Discussion in Working Party on European Union monographs and list	Jul 2015
(MLWP)	Sep 2015
	Nov 2015
	May/Jun 2016
	Sep 2016
	Nov 2016
	Jan 2017
	Mar 2017
	May 2017
	Sep 2017
	Nov 2017
	Jan 2018
Adoption by Committee on Herbal Medicinal Products (HMPC) for	March 2018
release for consultation	IVIAI CIT 2016
Start of public consultation	April 2018
End of consultation (deadline for comments). Comments should be	July 2018
provided using this template to hmpc.secretariat@ema.europa.eu	

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs;
	traditional use; Fragaria vesca L.; Fragaria moschata Weston; Fragaria viridis
	Weston; Fragaria x ananassa (Weston) Duchesne ex Rozier folium; wild
	strawberry leaf



BG (bălgarski): Горска ягода, лист

CS (čeština): jahodníkový list

DA (dansk): Jordbærblad
DE (Deutsch): Erdbeerblätter

EL (elliniká): χαμαικεράσου εδωδίμου φύλλο

EN (English): wild strawberry leaf

ES (español): fresa, hoja de ET (eesti keel): maasikaleht

FI (suomi): ahomansikka, lehti

FR (français): fraisier (feuille de) HR (hrvatski): list šumske jagode

HU (magyar): erdei szamóca levél

IT (italiano): Fragola foglia

LT (lietuvių kalba): Žemuogių lapai

LV (latviešu valoda): Meža zemenes lapas

MT (Malti): werqa tal-Frawli NL (Nederlands): Bosaardbei PL (polski): Liść poziomki

PT (português): morangueiro-bravo, folha

RO (română): frunză de frag SK (slovenčina): list jahody

SL (slovenščina): list navadnega jagodnjaka

SV (svenska): smultron, blad

IS (íslenska):

NO (norsk): markjordbærblad

### 1. European Union herbal monograph on Fragaria vesca L., Fragaria moschata West., Fragaria viridis West. and Fragaria x ananassa (West.) Duchesne ex Rozier, foliumName of the medicinal product

To be specified for the individual finished product.

# 2. Qualitative and quantitative composition 1,2

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC
	Fragaria vesca L.; Fragaria moschata West.; Fragaria viridis West.; Fragaria x ananassa (West.) Duchesne ex Rozier, folium (wild strawberry leaf)
	(i) Herbal substance
	Not applicable
	ii) Herbal preparations
	Comminuted herbal substance.

#### 3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

# 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product to increase the
	amount of urine to achieve flushing of the urinary tract

<sup>&</sup>lt;sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. <sup>2</sup> The material complies with the ÖAB(ref.: 2013: 076)

Well-established use	Traditional use
	as an adjuvant in minor urinary complaints.
	Indication 2)
	Traditional herbal medicinal product for symptomatic
	treatment of mild diarrhoea.
	The product is a traditional herbal medicinal product
	for use in the specified indications exclusively based upon long-standing use.

# 4.2. Posology and method of administration<sup>3</sup>

Well-established use	Traditional use
	Posology
	Adolescents, adults and elderly
	Indication 1)
	Herbal tea: 4-8 g of comminuted herbal substance in
	200 ml of water as a decoction, divided in 2 – 4 single
	doses
	Indication 2)
	Herbal tea: 1 g of comminuted herbal substance in 200
	ml of boiling water as a herbal infusion 2 - 3 times
	daily.
	The use in children under 12 years of age is not
	recommended (see section 4.4 'Special warnings and
	precautions for use').
	Duration of use
	Indication 1)
	If the symptoms persist longer than 2 weeks during
	the use of the medicinal product, a doctor or a
	qualified health care practitioner should be consulted.
	Indication 2)
	If the symptoms persist longer than 3 days during the
	use of the medicinal product, a doctor or a qualified

 $<sup>^3</sup>$  For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	health care practitioner should be consulted.
	Method of administration
	Oral use

#### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.
	Indication 1)
	Conditions where a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 12 years of
	age has not been established due to lack of adequate
	data.
	Indication 1)
	To ensure an increase of the amount of urine,
	adequate fluid intake is required during treatment.
	If complaints or symptoms such as fever, dysuria,
	spasms or blood in urine occur during the use of the
	medicinal product, a doctor or a qualified health care
	practitioner should be consulted.
	Indication 2)
	If recurrent diarrhoea or bloody stools occur, a
	doctor or a qualified health care practitioner
	should be consulted.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

#### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
	No fertility data available.

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	None known
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

# 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

#### 5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive
	2001/83/EC, unless necessary for the safe use of the
	product.Tests on reproductive toxicity, genotoxicity
	and carcinogenicity have not been performed.

# 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

# 7. Date of compilation/last revision

27 March 2018